Corganics is a Dallas-based life sciences company that makes scientifically formulated, physician-advised clinical CBD therapies sold exclusively through licensed healthcare professionals. Its broad-spectrum, THC-free products use Advanced Lipid Technology (A.L.T.) to improve bioavailability and are manufactured in cGMP-compliant, NSF-certified facilities with third-party testing and IRB-approved data. Founded in 2020 by pharmaceutical executives Chad Collins and Reggie Gatewood, the company aims to make CBD a trusted, clinic-grade therapy rather than a retail gamble.
CorVista Health is a medical technology company applying machine learning to cardiovascular diagnostics. Its FDA-cleared CorVista System is a non-invasive, point-of-care device that captures cardiac and hemodynamic signals and analyzes them in the cloud to assess the likelihood of coronary artery disease and pulmonary hypertension - delivering results in minutes, without radiation, contrast, injections, fasting, or exercise. The company aims to shorten the path from symptoms to diagnosis so patients can be treated earlier.
ExaCare AI is a New York-based healthcare technology company building an AI operating system for post-acute and senior care. Its suite of AI agents reads messy referral packets, recommends patient placements, automates reimbursement and documentation, and surfaces clinical risk so that care teams in skilled nursing, home health, and hospice spend less time on paperwork and more time on patients. Founded in 2022 by Laird Russell and Ben Willox, the company powers roughly 1,500-2,000 facilities nationwide and raised a $30M Series A led by Insight Partners in October 2025.
Fireflies.ai is a San Francisco-based AI meeting assistant that joins video and phone calls across Zoom, Google Meet and Microsoft Teams to record, transcribe, summarize and analyze conversations. Its bot captures speaker-labeled notes and action items, its AskFred assistant answers questions about past meetings, and its Perplexity-powered Live Assist offers real-time web answers during calls. Founded in 2016 by Krish Ramineni and Sam Udotong, the company reached a $1 billion valuation in 2025 while staying profitable and is used by teams across more than a million organizations.
Flawless is an AI filmmaking company building assistive tools that let studios re-edit dialogue and localize films into other languages while preserving the original actor's performance. Its products TrueSync and DeepEditor use computer vision and deep learning to reshape an actor's lip movements and expressions to match new lines or dubbed dialogue, removing the disconnect of traditional dubbing and subtitles. Co-founded by filmmaker Scott Mann and tech entrepreneur Nick Lynes, Flawless positions itself as a rights-first, consent-driven alternative to generative AI in cinema, endorsed by SAG-AFTRA and used across hundreds of studio productions.
SEEN Haircare is a dermatologist-developed hair and scalp care brand built on the idea that 'haircare is skincare.' Founded by Harvard-trained dermatologist Dr. Iris Rubin after her own haircare products caused facial breakouts, SEEN makes shampoos, conditioners, serums, masks and styling products clinically proven to be non-comedogenic (won't clog pores) and safe for sensitive skin. The brand is sold direct-to-consumer and at more than 700 Ulta Beauty doors, and closed a $9 million Series A in September 2024.
20x200 is a New York-based e-commerce company founded in 2007 by gallerist Jen Bekman to make art collecting accessible to everyone. It sells curated, limited-edition, museum-quality prints and photography by emerging, established and legendary artists, with prices historically starting at $20 (now from $35). The name comes from its original formula: the smallest size of each work printed in an edition of 200 and sold for $20. Part of Jen Bekman Projects, which also ran the Jen Bekman Gallery and the Hey, Hot Shot! photography competition.
858 Therapeutics is a clinical-stage biotechnology company in San Diego building small-molecule cancer drugs aimed at novel targets in DNA damage response, RNA modulation, and innate immunity. Its lead candidate, the oral PARG inhibitor ETX-19477, is in a first-in-human Phase 1/2 trial for advanced solid tumors and has won FDA Fast Track designation for BRCA-mutated, platinum-resistant ovarian cancer. Founded in 2019 by a serial team of San Diego drug developers, the company has raised $110 million across Series A and B financings.
Aampe is a San Francisco-based company building agentic AI infrastructure for personalized customer experiences. Instead of relying on generative AI, it assigns a dedicated reinforcement-learning agent to every individual user that continuously experiments and learns what content to send, when, and whether to send anything at all. The platform has deployed over 100 million agents across hundreds of consumer apps on four continents, helping product, data science, and lifecycle marketing teams move from rule-based campaigns to continuous, per-user adaptation.
AB180 is a Seoul-based marketing technology company building an AI stack for full-funnel app and game growth. Its flagship product, Airbridge, is a people-based mobile measurement and attribution platform (MMP) that connects ad spend to real revenue across web, app, PC and CTV, with AI-driven predictive LTV, fraud protection and deep linking. Founded in 2015, AB180 serves 600+ apps and games in more than 30 countries.
Abbot's (formerly Abbot's Butcher) is a Costa Mesa, California maker of premium plant-rich proteins built from 100% real food ingredients - pea protein, vegetables, herbs, spices, extra virgin olive oil and vinegars. Founded in 2017 by Kerry Song, the brand makes plant-based 'Chorizo,' Ground 'Beef,' Chopped and Fajita Chick'n, Italian 'Sausage' and high-protein veggie burgers that are free from the top nine allergens, seed oils, gums, preservatives and artificial flavors. With distribution in thousands of retail and foodservice locations including Whole Foods, Sprouts, Publix and Target, Abbot's positions clean, craveable plant food under a 'food as medicine' philosophy.
Abcuro is a clinical-stage biotechnology company in Newton, Massachusetts developing first-in-class immunotherapies that selectively deplete highly cytotoxic T cells implicated in autoimmune tissue damage and certain cancers. Its lead program, ulviprubart (ABC008), is a monoclonal antibody targeting the KLRG1 receptor, advanced primarily for inclusion body myositis (IBM) - a progressive muscle-wasting disease with no approved treatments - alongside pipeline work in T-cell large granular lymphocytic leukemia and T/NK-cell lymphomas.
Abram Scientific is a Menlo Park, California medical-device company building CoagCare, a portable point-of-care platform that reads the full blood-coagulation cascade - from clot formation through fibrinolysis - from a single drop of blood in under 10 minutes. By measuring blood viscoelasticity and density on single-use test cards inside a vibration-insensitive handheld meter, CoagCare aims to move coagulation testing out of the central lab and into trauma bays, ambulances, and MEDEVAC helicopters, helping clinicians decide the right transfusion or therapy at the right time.
AccessHope is a Duarte, California-based health benefits company, founded as a wholly owned subsidiary of City of Hope, that remotely delivers leading cancer expertise from National Cancer Institute (NCI)-designated Comprehensive Cancer Centers to employers and their covered employees. Rather than asking patients to switch doctors or travel, AccessHope connects local treating oncologists with subspecialists from elite centers, providing peer-to-peer case reviews and evidence-based treatment recommendations so patients can get the best cancer knowledge anywhere - without leaving home.
Accompany Health is a Bethesda, Maryland-based healthcare company building integrated primary, behavioral, and social care for low-income patients with complex medical needs. Founded in 2022 and publicly launched in January 2024 with $56 million in Series A funding, the company pairs a proprietary care-model technology platform with at-home and virtual visits, 24/7 support, and help navigating benefits like Medicaid and SNAP. It aims to be the kind of patient-centered, dignified care system that high-need, under-resourced patients rarely get.
Accorded is a San Francisco-based healthcare actuarial intelligence company that pairs actuarial expertise with software to simplify and scale value-based contracting. Its platform helps payers, providers, and digital-health companies forecast, contract around, and validate the financial value of care across the value-based contracting lifecycle. Founded in 2019 (originally as Cerebrae) by health actuary Frank Cheung and engineer Thomas Bedington, the company's flagship product, Acumen, turns raw claims, eligibility, and engagement data into standardized, actuarially rigorous, ready-to-use data assets so analytics teams can spend less time wrangling data and more time on strategy.
ACEINNA is a Massachusetts-based MEMS sensor company building high-performance, low-cost inertial measurement units (IMUs), GNSS/RTK precision-navigation systems, current sensors, and flow sensors. Spun out of MEMSIC in 2017 with a roughly $50M investment, ACEINNA is best known for its open-source OpenIMU platform and for shipping centimeter-accurate positioning solutions for autonomous vehicles and ADAS at a fraction of the price of legacy systems.
Adaptilens is a pre-clinical biotechnology company in Newton, Massachusetts developing the first biomimetic accommodating intraocular lens (A-IOL) - a soft, flexible artificial lens that responds to the eye's natural focusing signal from the ciliary muscle. Founded by ophthalmologist Dr. Liane Clamen, the company aims to replace the cataract-clouded natural lens with one that restores clear vision across near, intermediate, and distance ranges without glasses, contacts, or the halos and glare common to multifocal alternatives. Adaptilens raised a $17.5M Series A in April 2024 to advance its A-IOL toward first-in-human trials.
Adriel is an AI-powered ad operations (AdOps) and marketing intelligence platform that lets brands and agencies connect, monitor, and optimize digital advertising across hundreds of channels from a single dashboard. Founded in 2018 by Sophie Soowon Eom and Olivier Duchenne, the company pulls scattered campaign data from 600+ sources into real-time, automated reports, and has expanded into AI ad-creative generation (AdGen AI) and marketing automation. Adriel has served thousands of organizations - from small businesses to enterprises like LG Electronics - and raised about $20M in total funding, including a $13M Series B in 2022.
Aera Therapeutics is a Cambridge, Massachusetts biotech founded on a discovery from CRISPR pioneer Feng Zhang: human proteins that can self-assemble into capsid-like shells and ferry genetic cargo into cells. The company is building delivery platforms - protein nanoparticles, targeted lipid nanoparticles, and antibody-oligonucleotide conjugates - to solve the field's most stubborn problem: getting genetic medicines to the right tissue. Launched publicly in 2023 with $193M and led by Alnylam veteran Akin Akinc, Aera is betting that delivery, not the drug itself, is the bottleneck holding back the next generation of genetic medicine.
Aeromine Technologies builds a motionless, bladeless rooftop wind energy system for commercial and industrial buildings. Its 10-foot units sit along a roof's edge and use vertical airfoils to capture and amplify a building's own airflow, generating electricity silently and without spinning blades. The company says the system can produce up to 50% more energy than a comparable rooftop solar array while using roughly 10% of the roof space, and it is designed to complement, not replace, solar. Founded in 2021 and headquartered in Houston, Aeromine has run pilots with BASF and BMW Group and raised a ~$9M Series A led by Veriten in 2024.
Aetherflux is a San Carlos, California space and energy startup founded in 2024 by Robinhood co-founder Baiju Bhatt. It is building a constellation of small low-earth-orbit satellites that collect sunlight in space and beam the energy back to compact ground stations on Earth using infrared lasers rather than the giant geostationary microwave platforms imagined by earlier space-solar concepts. Backed by a $50 million Series A and early defense funding, the company aims to deliver electricity to places the grid cannot reach, beginning with forward operating bases, remote research stations, and disaster zones, and planned a first in-orbit power-beaming demonstration for 2026.
aifleet is an Austin-based, tech-driven trucking company that runs its own fleet on proprietary AI. Instead of selling software to carriers, it operates as a full-stack truckload carrier, using machine learning to book, price, and stack loads so trucks run fuller and drivers earn more with predictable weekly home time. The company reports roughly 40% higher truck utilization than the industry average and aims to fix the chronic inefficiency and high driver turnover that define long-haul freight.
Airgap Networks was a Santa Clara-based cybersecurity company that built an agentless Zero Trust segmentation platform to stop ransomware and lateral threat movement across enterprise IT, IoT, and OT networks. Using a patented DHCP-proxy architecture, it placed every device in a 'network of one' (a /32 segment) without agents, APIs, or infrastructure upgrades, and shipped an industry-first Ransomware Kill Switch. Founded in 2019 by Ritesh Agrawal and Satish Mohan, the company raised $18.6M before being acquired by Zscaler in April 2024 to extend Zscaler's Zero Trust SASE platform with firewall-free, east-west segmentation.
Akkio is a Cambridge, Massachusetts-based AI company that builds an AI-native platform for media agencies and data providers. It lets non-technical teams chat with their data, build no-code predictive models, segment audiences, simulate media plans, and generate campaign reports in minutes rather than weeks. Founded in 2019, Akkio started as a no-code machine learning tool for small businesses and has since refocused on automating the full campaign workflow for the advertising and media industry, with customers including Horizon Media, Havas, and LG Ad Solutions.
Akoonu is a Salesforce-native revenue intelligence company that helps B2B sales teams inspect their pipeline and build trustworthy forecasts without sending data to an external platform. Its RevWorks suite - covering pipeline reviews, forecasting, deal reviews, quota management, scenario modeling and an AI assistant called Oonu - runs 100% inside Salesforce, installs in under an hour, and positions itself as enterprise-grade forecasting without the enterprise price tag. Founded by serial entrepreneur Jeff Freund and based in Livingston, Montana, the company raised an $8M Series A in 2017 and counts enterprises like Honeywell, Thales and Avery Dennison among its customers.
Alara Imaging is a San Francisco healthcare technology company building a private compute platform for radiology. Its flagship product, the Alara Medical Imaging Gateway, is edge-orchestration software that sits inside a hospital and moves imaging data securely and bidirectionally between facilities and the cloud. Founded out of UCSF research, Alara serves as a CMS measure steward, giving health systems a HITRUST-certified, HIPAA- and SOC 2-compliant way to calculate and report new radiology quality measures - including a CMS-endorsed measure to standardize CT radiation doses and reduce avoidable cancer risk.
Albert is a Los Angeles-based personal finance app that bundles budgeting, banking, automated savings, investing, cash advances and human-plus-AI financial guidance into a single subscription. Founded in 2015 by Yinon Ravid and Andrzej Baraniak, it pairs software automation with real people - its 'Genius' experts - to help everyday Americans manage money, and has grown to serve tens of millions of users while raising roughly $177M, including a $100M Series C.
Alentis Therapeutics is a Swiss clinical-stage biotech built around a single, unusual biological target: Claudin-1 (CLDN1), a tight-junction protein that becomes exposed in both fibrotic tissue and solid tumors. Founded in 2019 on the discovery of physician-scientist Professor Thomas Baumert, the company develops first-in-class monoclonal antibodies and antibody-drug conjugates that bind exposed CLDN1 to reverse organ fibrosis and treat CLDN1-positive cancers. Headquartered in Allschwil near Basel with R&D roots in Strasbourg, Alentis has raised roughly $365 million across rounds, including a $181.4 million Series D in November 2024, and is running clinical trials for its lead antibody lixudebart (ALE.F02) and two ADCs, ALE.P02 and ALE.P03.
Alex is a San Francisco AI recruiting company whose voice and video agents conduct candidate interviews, screening, and scheduling at scale. Spun out of Y Combinator (W24, formerly Apriora), Alex automates the early, repetitive stages of hiring - phone screens, resume reviews, identity verification, and coordination - across video, phone, SMS, and WhatsApp in 26 languages. The platform has interviewed more than a million candidates for Fortune 100 companies, major banks, national restaurant chains, and Big 4 firms, cutting time-to-hire while letting human recruiters focus on relationships and final decisions.